Tarsa's $28M to give oral calcitonin another chance, following 2011 Novartis failure
This article was originally published in Scrip
Executive Summary
Tarsa Therapeutics, a small private US company, has raised the $28 million it needed to seek FDA approval (and following that, European approval) of its first drug – an oral recombinant salmon calcitonin, Ostora, for the treatment of postmenopausal osteoporosis, a multi-billion-dollar market. The withdrawal in November 2011 of a Phase III competitor oral formulation from Novartis clears the market for Tarsa.